top of page


TILZyme develops next generation Adoptive Immune Cell Therapy FucoTILs that address critical unmet needs for late stage metastatic cancer patients with solid tumors, helping patients fight cancer more effectively using their own immune systems, without the need for genetic engineering. 


Phase 1

Phase 2

Phase 3 REgistration



Breast Cancer


Colon Cancer


Pancreatic Cancer




(with T-cell Collaborator)

Lung Cancer


(with T-cell Collaborator)

Hematological Malignancies

TILZYME FucoTIL TZ102 Cell Therapy Products are Phase 2 Human Validation Trial Ready

TILs can recognize and kill cancer cells.  In cancer therapy, TILs are removed from a patient’s tumor, grown in large numbers in a laboratory, and then given back to the patient to help the immune system kill the cancer cells.

Targazyme’s FucoTILs are differentiated from other immune cell therapies thanks to our novel, patented, proprietary fucosylation platform technology which overcomes key technical constraints that have limited the Overall Response rate, Duration of Response, Relapse Free Survival outcomes associated with immunotherapies. Specifically FucoTILs traffick 300-600 percent more effectively and efficiently from the blood vasculature to the tumors (i.e more ‘therapeutic cells/medicine’ get to the disease sites. Compared to other adoptive cell therapies, FucoTILs also show increased synapse formation with the cancer tumors, increased expression of the ‘tumor killing machinery’ such as Granzyme B, Perforin, FASL, a 330-470 percent increased penetration of FucoTILs into solid tumors all resulting in increased tumor obliteration.


Compared to the use of other T-cells,  FucoTILs resulted in a 70 percent reduction in breast tumors compared to other T-cells and  a 62 percent reduction in melanoma cells in preclinical testing. 


By enabling a multifold immune cell trafficking and infiltration into solid tumors, Targazyme’s FucoTILs will also immune-potentiate  immunotherapies such as checkpoint inhibitors, MABs. These immunotherapies currently do not work well in  cold tumors (i.e. immune cell deserts) which accounts for 80-90 percent of solid tumors today. (Checkpoint Inhibitor outcomes in cold tumors  Breast: ORR:18.5%, pancreatic: ORR:5%, prostate : ORR: 1%. By enabling a multi-fold FucoTIL trafficking to tumors, cold tumors are transformed to warm/hot tumors (i.e. tumors with lots of immune cells) thereby immune-potentiating the immunotherapies for improved efficacy outcomes.


Targazyme and our collaborators at MD Anderson and Harvard have published fucosylated T-cell data in respected medical journals such as Clinical Cancer Research, Blood and IBJ. The data points to FucoTILs (ie the patients’ own immune cells) potentially treating/curing the patients of their solid tumor cancers.

bottom of page